Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1989-6-27
|
| pubmed:abstractText |
The results of a randomized, double-blind, placebo-controlled multicenter trial of fenofibrate in the treatment of type IV/V hyperlipoproteinemia are reported. Ten study centers in the United States recruited 147 adults with a history of type IV or V hyperlipoproteinemia. After a six- to 12-week dietary stabilization period and a four-week placebo period, patients whose 12-hour fasting total plasma triglyceride levels ranged from 350 to 1,500 mg/dl were continued in the study; 55 patients with levels of 350 to 499 mg/dl were placed in group A and 92 with levels of 500 to 1,500 mg/dl in group B. Patients in each group were randomly assigned to receive 100 mg of fenofibrate or placebo three times daily for eight weeks. In both groups A and B fenofibrate-treated patients showed statistically significant reductions in levels of total cholesterol, very-low-density lipoprotein cholesterol, total triglycerides, and very-low-density lipoprotein triglycerides, and significant increases in high-density lipoprotein cholesterol; patients in group B also showed a significant increase in low-density lipoprotein cholesterol levels. Sixteen of the 75 fenofibrate-treated patients and 11 of the 72 placebo patients reported adverse events that were potentially drug related; most of these were gastrointestinal and a few reported musculoskeletal and skin reactions. It is concluded that fenofibrate is an effective and safe agent in the treatment of type IV/V hyperlipoproteinemia.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0149-2918
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
69-83
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:2655907-Adolescent,
pubmed-meshheading:2655907-Adult,
pubmed-meshheading:2655907-Aged,
pubmed-meshheading:2655907-Cholesterol,
pubmed-meshheading:2655907-Clinical Trials as Topic,
pubmed-meshheading:2655907-Double-Blind Method,
pubmed-meshheading:2655907-Female,
pubmed-meshheading:2655907-Fenofibrate,
pubmed-meshheading:2655907-Humans,
pubmed-meshheading:2655907-Hyperlipoproteinemia Type IV,
pubmed-meshheading:2655907-Hyperlipoproteinemia Type V,
pubmed-meshheading:2655907-Male,
pubmed-meshheading:2655907-Middle Aged,
pubmed-meshheading:2655907-Propionates,
pubmed-meshheading:2655907-Random Allocation,
pubmed-meshheading:2655907-Time Factors,
pubmed-meshheading:2655907-Triglycerides,
pubmed-meshheading:2655907-United States
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.
|
| pubmed:affiliation |
Washington University, St. Louis, Missouri.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|